tiprankstipranks
Intellia Therapeutics (NTLA)
NASDAQ:NTLA

Intellia Therapeutics (NTLA) Ownership - Who Owns Intellia Therapeutics?

2,749 Followers

Intellia Therapeutics (NTLA) Ownership Overview

18.91%26.52%29.83%24.74%
18.91% Insiders
29.83% Other Institutional Investors
24.74% Public Companies and Individual Investors
The ownership structure of Intellia Therapeutics (NTLA) stock is a mix of institutional, retail and individual investors. Approximately 56.35% of the company’s stock is owned by Institutional Investors, 18.91% is owned by Insiders and 24.74% is owned by Public Companies and Individual Investors.
The ownership structure of Intellia Therapeutics (NTLA) stock is a mix of institutional, retail and individual investors. Approximately 56.35% of the company’s stock is owned by Institutional Investors, 18.91% is owned by Insiders and 24.74% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Mar 05, 2024
Eliana Clark
Evp, Cto
xxxxxxxxxxxxx
$19959
Mar 05, 2024
James Basta
Evp & Gc
xxxxxxxxxxxxx
$75778
Jan 05, 2024
Eliana Clark
Evp, Cto
xxxxxxxxxxxxx
$126707
Jan 05, 2024
Laura Sepp Lorenzino
Evp, Chief Scientific Officer
xxxxxxxxxxxxx
$162973

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2024
xxxxxxxxxxxxx
$113396
Mar 31, 2024
xxxxxxxxxxxxx
$302315147

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,989,282Institution11.39%283,413,583
10,978,440Institution11.38%283,133,968
8,634,979Institution8.95%222,696,108
8,013,043Institution8.31%206,656,379
4,400,822Institution4.56%113,497,199
3,296,787Institution3.42%85,024,137
2,311,459Institution2.40%59,612,528
1,905,000Institution1.97%49,129,950
1,163,722Institution1.21%30,012,390
967,732Institution1.00%24,957,808

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
8,013,043Institution8.31%206,656,379
3,296,787Institution3.42%85,024,137
1,905,000Institution1.97%49,129,950
1,163,722Institution1.21%30,012,390
967,732Institution1.00%24,957,808
934,307Institution0.97%24,095,778
727,740Institution0.75%18,768,415
652,320Institution0.68%16,823,333
648,627Institution0.67%16,728,090
447,447Institution0.46%11,539,658

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
8,371,901Institution8.68%215,911,327
2,606,539Institution2.70%67,222,641
2,848,899Institution2.95%60,909,461
2,346,661Institution2.43%57,798,260
2,120,118Institution2.20%52,218,506
2,328,212Institution2.41%49,777,173
1,345,913Institution1.40%28,775,620
1,325,432Institution1.37%28,337,736
896,708Institution0.93%22,085,918
691,090Institution0.72%17,823,211

FAQ

Who Owns Intellia Therapeutics (NTLA)?
According to the latest TipRanks data, approximately 29.83% of the company's stock is held by institutional investors, 18.91% is held by insiders, and 24.74% is held by retail investors.
    What percentage of Intellia Therapeutics (NTLA) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 29.83% of Intellia Therapeutics (NTLA) stock is held by institutional investors.
      What percentage of Intellia Therapeutics (NTLA) stock is held by retail investors?
      According to the latest TipRanks data, approximately 24.74% of Intellia Therapeutics (NTLA) stock is held by retail investors.
        Who owns the most shares of Intellia Therapeutics (NTLA)?
        Cathie Wood owns the most shares of Intellia Therapeutics (NTLA).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis